Pfizer Animal Health's acquisition of multiple product franchises in Europe from the Schering-Plough Corporation has been completed and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash.

The acquisition adds both biological and pharmaceutical products across the major animal health species including cattle, swine, equine and companion animal to Pfizer's portfolio. Pfizer has acquired certain rights to the products like Gletvax range of swine E.coli vaccines, equip range of equine Influenza and Tetanus vaccines, Covexin range of ruminant Clostridial vaccines, Lactovac -C, a cattle neonatal vaccine, Rabdomun - a Rabies vaccine, companion animal specialist products Insuvet and Eutha 77, Autoworm range of parasiticides, Coopers Spot-On in the UK, Coopers Spot-on CY in Ireland and Versatrine in France and Quadrisol 100 - anti-inflammatory product.

"This represents a significant expansion of our product portfolio and strengthens our long term commitment not just to veterinary surgeons, but also to farmers and pet owners," said Albert Bourla, Pfizer Animal Health's area president, Europe, Africa, Middle East. "Pfizer now has the most in-depth coverage of therapeutic areas in Europe, and the most highly recognized brands in the industry," Bourla said.

Pfizer, the world's largest research-based pharmaceutical company, also is a world leader in discovering and developing innovative animal prescription medicines and vaccines.